- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01989052
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
A Phase 1/2 Unblinded Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Lomustine for Bevacizumab-Naïve Adult Patients With Recurrent Malignant Glioma
This is a Phase 1/2 study of the combination of CTO with lomustine in patients with recurrent malignant glioma to be treated at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke. The Primary Objectives are:
- Phase 1: To determine the maximum tolerated dose (MTD) of CTO when combined with lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) who have not been previously treated with bevacizumab.
- Phase 2: To assess the efficacy of CTO (either in monotherapy or in combination with lomustine) compared to lomustine alone in patients with recurrent WHO grade IV malignant gliomas that have not been previously treated with bevacizumab based upon 6-month progression free survival (PFS6).
Note: This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and lomustine had been determined for this population. Phase 2 will not proceed.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the Phase 1 component of the study, we will conduct a dose-escalation study of the combination of CTO with lomustine among patients with recurrent malignant glioma (WHO grade III or IV). All patients will be bevacizumab-naïve. The dose escalation will be a standard "3+3" design to determine the MTD of CTO in combination with lomustine. The Phase 2 portion of this study will be a randomized screening study comparing CTO alone (Arm A) versus CTO with lomustine (Arm B) versus lomustine alone (Arm C) in patients with recurrent WHO grade IV malignant glioma who are bevacizumab-naïve. Subjects will be randomized with a treatment arm allocation ratio of 2:2:1.
Based on the results of patients who have already taken part in Phase 1 of the study, the Principal Investigator has decided to reduce the dose of lomustine used in combination with CTO in this study by 25% of the FDA-approved dose, due to hematologic side effects (side effects related to lower than expected blood counts). Therefore, the dose of lomustine received in combination with CTO is approximately 75% of the standard recommended dose.
Note: This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and lomustine had been determined for this population. Phase 2 will not proceed.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- The Preston Robert Tisch Brain Tumor Center at Duke
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Phase 1 portion: Patients must have recurrent histologically confirmed diagnosis of WHO grade III or IV malignant glioma with no more than 3 prior progressions
- Phase 2 portion: Patients must have recurrent histologically confirmed diagnosis of WHO grade IV malignant glioma (glioblastoma or gliosarcoma) with no more than 3 prior progressions
- Patients should have received optimal surgical management and radiotherapy prior to study enrollment
- Age ≥ 18 years
- Karnofsky Performance Status (KPS) ≥ 70%
- Bi-dimensionally measurable disease as assessed by magnetic resonance imaging based on RANO criteria
- Absolute Neutrophil Count (ANC) ≥ 1000 cells/µl, Platelets ≥ 100,000 cells/µl (without transfusion within 14 days before enrollment)
- Adequate renal function as indicated by the following: Serum creatinine < 1.25 times upper limit of normal or calculated creatinine clearance ≥ 50 ml/minute and urine dipstick for proteinuria < 2+ unless a 24-hour urine protein <1 g of protein is demonstrated
- Prothrombin time (PT) ≤ 1.5 x upper limit of normal (ULN) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN within 14 days prior to first study treatment for patients not receiving anti-coagulation. The use of full-dose oral or parenteral anticoagulants is permitted as long as the PT or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment.
- For patients on corticosteroids, they must be on a stable dose for 7 days prior to anticipated start of study drug, and the dose should not be escalated over entry dose level, if clinically possible.
- Signed informed consent approved by the Institutional Review Board
- No evidence of > grade 1 active central nervous system (CNS) hemorrhage on the baseline MRI or CT scan
- Female patients must not be pregnant or breast-feeding. Female patients of childbearing potential (defined as < 2 years after last menstruation or not surgically sterile) must use a highly effective contraceptive method (allowed methods of birth control, [i.e. with a failure rate of < 1% per year] are implants, injectables, combined oral contraceptives, intra-uterine device [intrauterine device (IUD); only hormonal], sexual abstinence or vasectomized partner) during the trial and for a period of > 6 months following the last administration of trial drug(s). Female patients with an intact uterus (unless amenorrhea for the last 24 months) must have a negative serum pregnancy test within 48 hours prior to first study treatment.
- Fertile male patients must agree to use a highly effective contraceptive method (allowed methods of birth control [i.e. with a failure rate of < 1% per year] include a female partner using implants, injectables, combined oral contraceptives, IUDs [only hormonal], sexual abstinence or prior vasectomy) during the trial and for a period of > 6 months following the last administration of trial drugs.
Exclusion Criteria:
- Pregnancy or breastfeeding
- Treated previously with vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) therapies, including antibodies and tyrosine kinase inhibitors
- Prior disease progression on lomustine
- Taking cytochrome P450 3A4 (CYP3A4) inducers and moderate or strong inhibitors. To note: Corticosteroids are allowed, as long as patients have been on a stable dose for 7 days prior to anticipated start of study drug, and the dose should not be escalated over entry dose level, if clinically possible.
- Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids
- Active infection requiring IV antibiotics 7 days before enrollment
- Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin
- Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 consecutive scans or histopathologic confirmation
- Treated with immunotherapeutic agents, vaccines, or monoclonal antibody (MAb) therapy within 4 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Treated with alkylating agents within 4 weeks before enrollment or treated within 1 week before enrollment with daily or metronomic chemotherapy, unless the patient has recovered from the expected toxic effects of such therapy
- Prior chemotherapy (non-alkylating agents) within 2 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Current, recent (within 4 weeks of the first infusion of this study), or planned use of an experimental drug, unless the patient has recovered from the expected toxic effects of such therapy
Vascular endothelial growth factor (VEGF) Inhibitor-Specific
Exclusion Criteria are:
- Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) within 28 days of first study treatment
- Prior history of hypertensive crisis, hypertensive encephalopathy, reverse posterior leukoencephalopathy syndrome (RPLS)
- Prior history of gastrointestinal perforation or abscess
- Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment
- History or evidence upon physical/neurological examination of central nervous system disease (e.g. seizures) unrelated to cancer unless adequately controlled by medication or potentially interfering with protocol treatment
- Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment
- History of pulmonary hemorrhage/hemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month of first study treatment
- History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation)
- Current or recent (within 10 days of study enrollment) use of aspirin (>325 mg/day), clopidogrel (>75 mg/day) or equivalent. Prophylactic or therapeutic low molecular weight heparin (LMWH) is allowed
- Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study
- Minor surgical procedure, e.g. stereotactic biopsy, within 7 days of first study treatment; placement of a vascular access device, within 2 days of first study treatment
- History of intracranial abscess within 6 months prior to first study treatment
- History of active gastrointestinal bleeding within 6 months prior to first study treatment
- Serious, non-healing wound, active ulcer, or untreated bone fracture
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1: CTO and lomustine
The combination of CTO with the standard dosing of 100 mg/m2 of lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have not previously received bevacizumab as treatment for their disease
|
Other Names:
Other Names:
|
Experimental: Phase 2: CTO alone
CTO alone at the MTD established in the Phase 1 portion of this study
|
Other Names:
|
Experimental: Phase 2: CTO and lomustine
CTO at the same daily dose of as in the CTO alone arm in combination with 110 mg/m2 oral lomustine every 6 weeks
|
Other Names:
Other Names:
|
Experimental: Phase 2: Lomustine alone
Oral lomustine alone at 110 mg/m2 every 6 weeks
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Determine the maximum tolerated dose (MTD) of CTO when combined with lomustine
Time Frame: 1 year
|
A standard "3+3" design to determine the MTD of CTO in combination with lomustine. Subjects will be administered CTO orally on a continuous daily dosing schedule, while subjects will receive oral lomustine (110 mg/m2) every 6 weeks. Cohorts of 3-6 subjects will accrue at each dose level of CTO, beginning with 225 mg/m2, until MTD is defined. The MTD is the highest dose level at which ≤ 1 out of 6 experienced a dose limiting toxicity (DLT). MTD is defined as the highest dose level at which ≤ 1 out of 6 experienced DLT. |
1 year
|
Phase 2: Percentage of subjects who remain alive and progression-free at 6 months
Time Frame: 6 months
|
Percentage of participants surviving six months from date of randomization without progression of disease.
Progression-free survival (PFS) was defined as the time from date of randomization to the date of the first documented progression according to the Response Assessment in Neuro-Oncology (RANO) criteria, or to death due to any cause.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 2: Percentage of subjects who experience a dose-limiting toxicity (DLT) during any cycle of protocol treatment
Time Frame: 2 years
|
All toxicities will be collected using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DLTs will be defined as any of the following events that are possibly, probably, or definitely attributable to CTO or lomustine: Non-hematologic:
Hematologic:
|
2 years
|
Phase 2: Median Overall Survival (OS)
Time Frame: 2 years
|
Time in months from date of randomization to date of death due to any cause.
Patients alive as of the last follow-up had OS censored at the last follow-up date.
Median OS was estimated using a Kaplan-Meier curve.
|
2 years
|
Phase 2: 12 month Overall Survival (OS)
Time Frame: 12 months
|
Percentage of participants surviving 12 months from date of randomization.
OS was defined as time from randomization to the date of death due to any cause.
|
12 months
|
Phase 2: Percentage of subjects with best overall response (BOR) of complete response (CR) and partial response (PR)
Time Frame: 2 years
|
Response is based on Response Assessment in Neuro-Oncology (RANO) criteria as determined by investigator assessment.
A confirmation of response was not required.
Complete Response was defined as complete disappearance on MRI/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.
Partial Response was defined as greater than or equal to 50% reduction in tumor size on MRI/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.
|
2 years
|
Phase 2: Median PFS
Time Frame: 2 years
|
Time in months from date of randomization to the date of first progression according to RANO criteria, or to death due to any cause.
Patients alive who had not progressed as of the last follow-up will have PFS censored at the last follow-up date.
Median PFS was estimated using a Kaplan-Meier curve.
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Lomustine
- Carboxyamido-triazole
Other Study ID Numbers
- Pro00047969
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Glioma (WHO Grade III or IV)
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
Beijing Tiantan HospitalZhongSheng BioTech Inc.RecruitingWHO Grade III Gliomas | WHO Grade IV GliomasChina
-
Annick DesjardinsTactical Therapeutics, Inc.TerminatedMalignant Glioma (WHO Grade III or IV)United States
-
Michael Vogelbaum, MD, PhDInfuseon Therapeutics, Inc.CompletedMalignant Glioma | WHO Grade III or IV Recurrent GliomaUnited States
-
Susan ChangGE Healthcare; Sigma-Aldrich; Phillips-MedisizeRecruitingRecurrent WHO Grade III Glioma | WHO Grade III Glioma | WHO Grade II Glioma | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Metastatic Malignant Neoplasm in the Brain | Low Grade Glioma | PartnerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II GliomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...RecruitingGlioblastoma | WHO Grade III Glioma | WHO Grade II GliomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGlioblastoma | Malignant Glioma | WHO Grade III GliomaUnited States
Clinical Trials on CTO
-
Corindus Inc.TerminatedCoronary Artery Disease | Percutaneous Coronary Intervention | Chronic Total Occlusion of Coronary ArteryUnited States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingChronic Total Occlusion of Coronary ArteryChina
-
Leif ThuesenRecruitingHeart Failure | Angina Pectoris | Chronic Total Occlusion of Coronary ArteryDenmark
-
SoundBite Medical Solutions, Inc.Completed
-
Universitätsmedizin MannheimIHF GmbH - Institut für Herzinfarktforschung; Herzzentrum LahrNot yet recruitingCoronary Artery Disease | Heart Failure | Chronic Total Occlusion
-
Kerckhoff Heart CenterInstitute of Cardiology, Warsaw, Poland; University of Giessen; University Hospital...CompletedCoronary Artery DiseaseGermany, Poland
-
Yale UniversityBoston Scientific CorporationTerminatedSymptomatic Femoro-popliteal Chronic Total OcclusionUnited States
-
Ureca BVTerminated
-
National Institute of Cardiology, Warsaw, PolandRecruitingCoronary Artery Disease | Percutaneous Coronary Intervention | Coronary OcclusionPoland
-
AngioSafe, Inc.Veranex, Inc.RecruitingPeripheral Arterial Disease | Peripheral Artery OcclusionUnited States